One of the major challenges of schistosomiasis chemotherapy is the efficacy of treatment at the initial phase of the disease. It is well known that *Schistosoma mansoni* development from the schistosomulum stage to the adult worm is accomplished through evolutive stages, with morphological changes and a large body growth. [@B09] using experimental infection in rats, rabbits and monkeys observed that this development occurs in an asynchronous way.

Several authors have already demonstrated that at the initial stage of development (immature worms) *S. mansoni* is less susceptible to chemotherapeutic action, including oxamniquine and praziquantel ([@B23], [@B17], [@B19], [@B16], [@B05], [@B10]).

[@B17] demonstrated that *S. mansoni* immature worm is less susceptible at least to six antischistosomal drugs: antimonium and potassium artesunate, hycanthone, oxamniquine, niridazol, amoscanato and praziquantel, used at doses considered curative against adult worms. The six tested drugs were ineffective against worms already housed in the portal system. It is noteworthy that hycanthone, oxamniquine, praziquantel and niridazol showed activity against schistosomula up to two-week-old. It was observed that there was a greater activity against mature adult worms than in five-six-week-old worms. An important result was the total or partial activity on two-five-week-old worms.

Treatment of infection at the initial stages would bring a great advantage for vertebrate hosts, since it would avoid production of eggs and, consequently, formation of granulomas, which are the fundamental elements of the pathology of the disease ([@B04], [@B22], [@B08], [@B06]).

The fundamentals of the present study are based on the well established biological fact that immature worms, by reasons related to time required to reach the portal-hepatic system, coming from the lungs, present a marked evolutive asynchronism ([@B09], [@B03]). This fact could explain, at least in part, the difficulty of conventional antischistosomal drugs, administered at the initial phase of infection, to eliminate with efficacy all the parasites, considering the difference of susceptibility to the drug regarding the mentioned stage of worm development.

The procedure related to counting of schistosomula recovered by perfusion of animals previously infected with *S. mansoni* cercariae and their classification based on morphological criteria (1st-6th stages), according to intestinal development generating the percentage related to each evolutive stage in the portal system, is called schistogram ([@B03]).

This study evaluated the activity of oxamniquine, praziquantel and artesunate, administered alone or in association, in the initial phases of infection using schistogram as a parameter, trying to identify the developmental stages that are most vulnerable or resistant to drug action.

For treatment three antischistosomal drugs, which are currently used for schistosomiasis treatment, were selected oxamniquine, praziquantel and artesunate, administered alone or in association ([@B21], [@B12], [@B18]).

MATERIALS AND METHODS
=====================

*Infection of mice -* Swiss female mice, weighing approximately 20 g, infected with 200 ± 10 *S. mansoni* cercariae (LE strain), by subcutaneous route, or 50 cercariae when mice were sacrificed 100 days after infection, were used in this study.

*Treatment of animals* - Oxamniquine, praziquantel and artesunate were administered in monotherapy or in association (praziquantel and artesunate), always with single dose and by oral route. The schedules utilised for treatments were as follows: oxamniquine - 200 mg/kg or 400 mg/kg weight in monotherapy, praziquantel - 400 mg/kg or 800 mg/kg in monotherapy or in association with 300 mg/kg or 600 mg/kg artesunate, which was also used in monotherapy with the same doses as the association.

The animals were treated 14, 15, 21 or 23 days post-infection and the perfusion of mice was performed five, 42 or 100 days after treatment for collection, counting and classification of worms.

*Evaluation of schistosomicidal activity -* In order to evaluate the activity of drugs at the pre-patent (pre-postural) phase of infection, the animals were submitted to euthanasia by cervical fracture (experimental groups and controls in all the schedules). After that, the animals were submitted to perfusion of the mesenteric veins and liver, according to the technique prescribed by [@B14] for worm recovery. After perfusion of the portal system, the recovered immature worms were counted and classified using a stereomicroscope. Morphological criteria, based on the development of the digestive tract of the parasite after ingestion of blood, were used for its classification regarding its evolutive stage, constituting the schistogram ([@B03]).

For activity evaluation at the patent phase, perfusion of mesenteric veins and liver was performed aiming at recovering and counting adult worms (Pellegrino & Siqueira 1956). The livers were crushed between slide and coverslip and observed under a stereomicroscope for counting of dead worms; fragments from the distal portion of the small intestine, measuring approximately 1 cm, were compressed between two plastic slides and observed under optical microscope for detection of *S. mansoni* eggs at different evolutive stages ([@B15]).

Groups of untreated infected mice (control of infection) were kept in all the schedules and were submitted to the same procedure for treated animals, except treatment.

Schistogram changes were observed taking into account differences in the average of recovered immature worms, at each evolutive stage after comparison to untreated control and percentage in reduction of recovered adult worms of treated groups in relation to untreated control.

The average of recovered worms, distribution of worms in the liver and mesentery, percentage of dead worms in the liver and of oogram changes were indicators of drug activity on the adult worm ([@B13]).

*Statistical analyses -* All the results were submitted to normality test. Kruskal-Wallis test, followed by Dunn\'s multiple comparison, were applied to non-parametric data, whereas Pearson\'s X^2^ test and ANOVA, followed by Tukey\'s multiple comparisons, were applied to parametric data.

*Ethics -* The guidelines of the Ethical Committee for the use of experimental animals of Oswaldo Cruz Foundation were followed (CEUA L-018/09).

RESULTS
=======

The results obtained in all the experiments are presented in [Tables I-IV](#t01){ref-type="table"}.

TABLE IDistribution of young worms recovered from mice infected with 200 Schistosoma mansoni cercariae treated with single dose by oral route as monotherapy and submitted to euthanasia (treated and control groups) five days after treatmentAnimals (n)Distribution of schistosomules per evolutive stage (%)Treatment schedule (mg/kg)Treated after infection (days)TreatedExaminedMean of worm (% reduction)123456NIOxamniquine 20015131312.5 (57)^*a*^0.512.236.850000.5Artesunate 30015131310.0 (65.6)^*a*^3.88.510.8^*b*^57.72.3016.9^*b*^Praziquantel 40015131316.5 (43.3)^*a*^0.9624.267.50.900.5Control\--1229.1 (0)3.17.226.4590.304Oxamniquine 20023131237.0 (31.2)000.714.637.846.80Artesunate 30023131327.8 (48.3)^*a*^00.30.31331.654.80Praziquantel 40023131342.7 (20.6)00213.538.346.20Control\--1153.8 (0)00.31.28.932.956.70Oxamniquine 4001513933.3 (43.7)^*a*^1.71724.357^*a*^006Artesunate 60015131224.1 (59.2)^*a*^6.219^*a*^12.1^*a*^35.6^*a*^0027^*b*^Praziquantel 8001513928.9 (51.1)^*a*^1.513.829.654.6^*a*^000.4Control\--1149.4 (16.4)0.97.418.870.20.602.2Oxamniquine 40023131228.9 (51.1)^*a*^00.3427.7^*a*^41.813^*a*^13.3^*a*^Artesunate 60023131225.8 (56.3)^*a*^00.30.34.9^*a*^32^*c*^23.6^*a*^38.8^*b*^Praziquantel 80023131340.5 (31.6)^*a*^00.61.410.561.225.8^*a*^0.4Control\--1259.1 (0)00.11.310.44245.11[^1]

TABLE IIAdult worm burden recovered from mice infected with 200 Schistosoma mansoni cercariae treated with single dose by oral route as monotherapy and submitted to euthanasia (treated and control groups) 42 days after treatmentAnimals (n)Worms n (% reduction)Treatment schedule (mg/kg)Treated after infection (days)TreatedExaminedMean of worm (% reduction)MalesFemalesImmature wormsOxamniquine 20015131233.7 (46.8)^*a*^194 (49.7)^*a*^191 (53.8)^*a*^19 (4.7)Artesunate 30015131322.5 (61.4)^*a*^129 (66.5)^*a*^134 (66.5)^*a*^45 (15.4)^*a*^Praziquantel 40015131241.2 (34.9)^*a*^244 (36.8)^*a*^223 (37.2)39 (7.7)Control\--1358.4 (0)386 (0)355 (0)18 (0)Oxamniquine 20023121252.4 (25.7)228 (39.6)^*a*^273 (39.3)^*a*^128 (20.3)^*a*^Artesunate 30023121143.7 (43.2)^*a*^200 ( 47.5)^*a*^248 (44.9)^*a*^33 (6.9)Praziquantel 40023121252.4 (25.7)277 (27.3)282 (37.8)^*a*^70 (11.1)Control\--1270.6 (0)381 (0)450 (0)18 (0)Oxamniquine 40015151540.8 (55.1)^*a*^233 (65.8)^*a*^270 (60.4)^*a*^104 (16.8)Artesunate 60015131535.1 (61.4)^*a*^241 (63.6)^*a*^261 (61.7)^*a*^24 (4.6)Praziquantel 80015151553.8 (40.9)^*a*^339 (48.8)^*a*^362 (46.9)^*a*^52 (6.9)Control\--1497.5 (0)662 (0)682 (0)21 (0)Oxamniquine 40023141320.9 (75)^*a*^64 (88.9)^*a*^113 (77.3)^*a*^95 (34.9)^*a*^Artesunate 600231414327 (57.9)^*a*^141 (76.6)^*a*^132 (73.4)^*a*^185 (40.4)^*a*^Praziquantel 80023141256.8 (37.4)^*a*^329 (42.9)^*a*^314 (36.8)38 (5.6)Control\--1383.8 (0)577 (0)497 (0)15 (0)[^2]

TABLE IIIDistribution of young worms recovered from mice infected with 200 Schistosoma mansoni cercariae treated with single dose by oral route as monotherapy and combination of drugs and submitted to euthanasia (treated and control groups) five days after treatmentAnimals (n)Distribution of schistosomules per evolutive stage (%)Treatment schedule (mg/kg)Treated after infection (days)TreatedExaminedMean of worm (% reduction)123456NIPraziquantel 40014111029.3 (32.6)0.3524680.301.6Praziquantel 80014111123.5 (46)^*a*^0.44.73154.3^*a*^6.603.1Artesunate 30014111017.9 (58.9)^*a*^1.28.716.9 ^*a*^53.5^*a*^0.6019.2^*a*^Artesunate 600141197.7 (82.3)^*a*^1.420.3^*a*^7.2 ^*a*^34.8^*a*^1.4034.8^*a*^Praziquantel 400 + artesunate 3001412129.8 (77.5)^*a*^2.516.929.7 ^*a*^42.4^*a*^008.5^*a*^Praziquantel 800 + artesunate 6001412119.1(79.1)^*a*^15.918.855.4^*a*^1017.8^*a*^Control\--1243.5 (0)0.63.818.673.92.300.8Praziquantel 40021111057.6 (5.6)01.73.834.944.413.7^*a*^1.4Praziquantel 80021111136.0 (41)^*a*^00.39.634.145.49.6^*a*^0.8Artesunate 30021111126.9 (55.9)^*a*^00.31.410.129.414.5^*a*^44.3^*a*^Artesunate 60021121220.6 (66.2)^*a*^00.8015.435.24.9^*a*^43.7^*a*^Praziquantel 400 + artesunate 30021121129.3 (52)^*a*^00.93.42727.64.7^*a*^36.6^*a*^Praziquantel 800 + artesunate 60021121119.2 (68.5)^*a*^00.54.319.938.98.1^*a*^28.4^*a*^Control\--1161 (0)00.33.321.637.935.21.8[^3]

TABLE IVResults obtained using mice experimentally infected with 50 Schistosoma mansoni cercariae treated by oral route single dose as monotherapy 14 or 21 days after infection and sacrificed 100 days after infectionAnimals (n)Distribution of worms (%)Treatment schedule (mg/kg)Treated after infection (days)TreatedExaminedMean of worm (% reduction)MesenteryLiverDead worms in the liver (%)Oogram changes (%)Oxamniquine 2001415117.1 (65)^*a*^86.213.8045.5^*a*^Artesunate 300141597.0 (65.3)^*a*^94.95.1011.1Praziquantel 40014151312.6 (37.6)97.62.400Oxamniquine 2002115117.4 (63.6)^*a*^93.66.4027.3Artesunate 3002115135.2 (74.3)^*a*^95.64.4016.4Praziquantel 400211579.3 (54)^*a*^82.417.6028.6Control\--1320.2 (0)88.511.500Oxamniquine 4001415115.2 (67.9)^*a*^76.223.89.563.6^*a*^Artesunate 6001415134.5 (72.2)^*a*^8119015.4Praziquantel 800141589.5 (41.4)76.923.100oxamniquine 4002115126.8 (58)^*a*^85.214.8058.6^*a*^Artesunate 6002115115.7 (64.8)^*a*^87.312.7027.3Praziquantel 800211577.9 (51.2)^*a*^83.616.4014.3Control\--1516.2 (0)86.113.900[^4]

Except for praziquantel, administered at the dose of 400 mg/kg, 15 or 23 days post-infection, it was observed a significant decrease in the mean number of worms recovered by perfusion in all the other therapeutic schedules used. Oxamniquine reduced from 70.2-57% the young worms at fourth evolutive stage, when treatment was administered 15 days after infection and it was observed a statistically significant increase in the percentage of worms (4th evolutive stage) when the drug was used 23 days after infection; the drug also reduced 70% of the worms at the sixth evolutive stage and increased from 1% (control group) to 13.3% (oxamniquine 400 mg/kg) the percentage of unidentified worms due to intestinal damages (NI), when treatment was administered 23 days post-infection. Treatment with artesunate was responsible for a significant decrease in the percentage of young worms at third stage (300 mg/kg, treatment on 15 days after infection), as well as an increase in the percentage of worms at second stage; there was also a decrease about 30% and 50% in the percentage of worms at third and fourth stages, respectively (dose of 600 mg/kg, treatment 15 days after infection) and diminished by almost half the percentage of worms at fourth, fifth and sixth evolutive stages (dose of 600 mg/kg, treatment 23 days after infection). The percentage of immature worms, which could not be assigned to any of the six stages and were considered as NI, was at most 4% in untreated mice. On the other hand, a significant increase in the percentage of NI could be observed, varying from 16.9% (animals treated 15 days post-infection with 300 mg/kg artesunate) to 38.8%, when artesunate (600 mg/kg) was administered 23 days after infection. In relation to the other two drugs, only oxamniquine (400 mg/kg, treatment 23 days after infection) showed a significant increase in the percentage of NI (13%, p \< 0.05) ([Table I](#t01){ref-type="table"}).

In all the schedules using different doses of oxamniquine, artesunate and praziquantel, 15 or 23 days post-infection, activity evaluation performed 42 days after infection showed a significant reduction in the mean of recovered worms, varying from 25.7% (when 200 mg/kg oxamniquine or 400 mg/kg praziquantel were used) to 75% when treatment with 400 mg/kg oxaminiquine was administered 23 days after infection. The animals treated with 200 mg/kg or 400 mg/kg oxamniquine, or with 300 mg/kg or 600 mg/kg artesunate, 15 or 23 days after infection, showed a significant statistical reduction in the number of collected male and female worms. Treatment with praziquantel resulted in significant reduction only in the number of male worms, about 40% in reduction when doses of 400 mg/kg or 800 mg/kg were administered 23 or 15 days post-infection, respectively.

The percentage of immature worms collected reached a maximum of 2.4% in untreated mice of the control group. Treatment with 300 mg/kg artesunate, 15 days after infection or 600 mg/kg 23 days after infection, significantly increased the percentage of immature worms (15.4% and 40.4%, respectively). Treatment with 200 mg/kg or 400 mg/kg oxamniquine, 23 days post-infection, significantly increased the percentage of recovered immature worms (20.3% and 34.9%, respectively). When treatment with 400 mg/kg oxamniquine was administered 15 days after infection, there was a significant statistical increase of 16.8% in the percentage of immature worms ([Table II](#t02){ref-type="table"}).

In the experiments using praziquantel and artesunate in monotherapy or in association, it was observed a significant reduction in the mean number of worms collected by perfusion, except for the groups treated with 400 mg/kg praziquantel, 14 or 21 days after infection. When treatments performed in monotherapy were compared with those ones using drugs in association, the results related to decrease in the average of worms were similar. Praziquantel used in monotherapy significantly reduced the percentage of fourth stage worms (400 mg/kg and 800 mg/kg administered 21 days after infection); artesunate in monotherapy was more effective reducing the number of worms (3rd and 4th stages), when used at the doses of 300 mg/kg or 600 mg/kg, 21 days after infection. It was observed a significant increase in the number of young worms, which were not identified due to intestinal damages in animals treated with artesunate in monotherapy or with other drug in association, but not in treatment schedules with only praziquantel ([Table III](#t03){ref-type="table"}).

Mice treated with oxamniquine (200 mg/kg or 400 mg/kg), artesunate (300 mg/kg or 600 mg/kg) or praziquantel (400 mg/kg or 800 mg/kg), 14 or 21 days post-infection, and evaluated 100 days after infection, presented a significant reduction in the number of worms (37-74%) in relation to the control group. No significant difference in reduction of the average of worms between the treated groups at different schedules could be observed. Worm distribution in mesentery and liver was similar to the control group and no dead worms were detected in the liver. Nevertheless, the oogram was altered in all the groups, except in those treated with praziquantel on days 14 post-infection ([Table IV](#t04){ref-type="table"}).

It is important to emphasise that even performing perfusion 100 days after infection, a part of the recovered worms in treated groups (400 mg/kg oxamniquine and 600 mg/kg artesunate) remained small and with fragile aspect. Most of the females were with a clear-looking intestine, seeming to be female immature worms. In the group treated with artesunate (600 mg/kg, 21 days post-infection) 16 out of 34 (47.1%) females presented immature characteristics, whereas 14 out of 36 (38.9%) females seemed to be immature in the group treated 14 days after infection. In the group treated with oxamniquine (400 mg/kg, 21 days post-infection) 22 out of 49 (44.9%) females showed an immature aspect, while eight out of 28 (28.6%) females showed an immature aspect in the group treated 14 days after infection.

DISCUSSION
==========

The asynchronous development of *S. mansoni* at the pre-patent phase was clearly observed in this study and the distribution of the immature worms recovered in the untreated control groups was similar to that reported by [@B03].

These results here presented show that the drug interferes in the worm development, slowing or blocking the development of parasites, since significant percentages of worms with an immature aspect were detected up to 100 days after infection. This original finding has important implications in the fields of pathology, diagnosis and epidemiology of schistosomiasis.

Oogram alteration was observed in worms of the group treated with oxamniquine (200 mg/kg or 400 mg/kg), 14 or 21 days after infection, and submitted to euthanasia 42 days post-infection, indicating that treatment interfered with sexual maturation of the worms, since immature females were recovered.

In the animals treated with 300 mg/kg or 600 mg/kg artesunate, 14 or 21 days post-infection, a small percentage of oogram changes could be observed, although not statistically significant, is of relevance. According to [@B02], treatment with artesunate, at the postural phase, is capable of interrupting egg-laying only temporarily.

Praziquantel and derivatives of artesunate shown to be effective in different stages of worm development, being suggested that these drugs would be more efficacious when administered in association than in monotherapy ([@B11], [@B01]). Promising results were obtained with praziquantel/artesunate in association, when administered in *S. mansoni* and *Schistosoma japonicum* infected mice, presenting immature and mature worms, simultaneously ([@B20]).

These data were not corroborated by [@B07] in infected patients, in an endemic area for *S. mansoni*. In the present study, the results obtained with combination of 400 mg/kg praziquantel + 300 mg/kg artesunate, or 800 mg/kg praziquantel + 600 mg/kg artesunate, administered 14 or 21 days post-infection, did not show therapeutic advantages, since the profile presented by drug associations was similar to that observed when artesunate was administered alone. Perhaps, a better result can be obtained if the association is used in mixed infections, with adult and immature worms ([@B21]).

The experimental chemotherapy at the pre-postural phase of *S. mansoni* is a field of great importance for development of antischistosomal drugs, due to its potential to eliminate the parasitism before lying of eggs, which cause the major injuries responsible for the disease - the granulomatous inflammatory reactions ([@B08], [@B06]). Thus, experimental chemotherapy is of the utmost importance and deserves a greater number of studies in this direction.

Worms treated at the early phase of infection (unfertile worms), 100 days post-chemotherapy, could maintain an immunological response, as well as the presence of circulating antigens in blood, even in absence of eggs in the faeces.

These findings represent a major cause of confusion regarding the interpretation of schistosomiasis mansoni diagnosis: the absence of eggs in the faeces, but maintenance of specific immune response, the presence of circulating antigens and genetic material of *S. mansoni* worms (detected by polymerase chain reaction techniques).

The results obtained allow us to conclude that the schistogram method used in this study proved to be a useful tool for experimental evaluation of the activity of antischistosomal drugs, at the early stages of infection, besides being a good model to investigate which of the evolutive stages are more sensitive to antischistosomal drugs.
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[^1]: a : statistically signiﬁcant difference in relation to control (p ≤ 0.05); b : statistically signiﬁcant difference of artesunate in relation to praziquantel and oxamniquine (p ≤ 0.05); c : statistically signiﬁcant difference of artesunate in relation to praziquantel (p ≤ 0.05); NI: schistosomules with damaged intestines that did not allow their identification.

[^2]: a : statistically signiﬁcant difference in relation to control (p ≤ 0.05).

[^3]: a : statistically signiﬁcant difference in relation to control (p ≤ 0.05); NI: schistosomules with damaged intestines that did not allow their identification.

[^4]: a : statistically significant difference in relation to untreated control (p ≤ 0.05).
